Bristol will fall an extra 10%

16 lut

BMY has reported somewhat disappointing results for 2025, and the investors' disappointment is evident in the breakdown of the double top that had formed.

This suggests a likely drop of about 10% in the stock price, although it doesn't affect the long term. The weaker sales in generic drugs should be offset by additional cost reductions, but nobody likes holding stocks that rely on cutting costs...

We suggest a short-term sell to take advantage of this 10% drop and then wait to see how BMY's price reacts.

7 mar

Transakcja zakończona: osiągnięto poziom stop

A fake breakout happened, this is a bull signal that moved the price to the opposite side of the channel.